There have been reports of leakage from CCT syringes used for several GlaxoSmithKline Inc. vaccines during vaccine preparation or administration. Although the leakage does not pose a concern for the vaccine sterility, there is a potential risk of underdosing associated with administration of a vaccine from a leaking syringe that may leave patients inadequately protected from disease after vaccination.
Products affected*
|
Product (medicinal ingredient(s)) |
DIN# |
|
BOOSTRIX (combined diphtheria, tetanus, acellular pertussis (adsorbed) vaccine) |
02247600 |
|
BOOSTRIX-POLIO (combined diphtheria, tetanus, acellular pertussis (adsorbed) and inactivated poliomyelitis vaccine) |
02312557 |
|
HAVRIX (hepatitis A vaccine, inactivated) |
02187078 |
|
HAVRIX Junior (hepatitis A vaccine, inactivated) |
02231056 |
|
INFANRIX-IPV (combined diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine) |
02241284 |
|
INFANRIX-IPV/HIB (combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, Haemophilus influenzae type b vaccine) |
02257122 |
|
INFANRIX-hexa (combined diphtheria and tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis and adsorbed conjugated Haemophilus influenzae type b vaccine) |
02253852 |
|
TWINRIX (combined hepatitis A (inactivated) and hepatitis B (recombinant) vaccine) |
02230578 |
|
TWINRIX Junior (combined hepatitis A (inactivated) and hepatitis B (recombinant) vaccine) |
02237548 |
*Note: In addition to the above-noted products, 1 lot of ENGERIX-B (Adult), which was released in Canada for shortage mitigation, provided in a syringe format (
Lot AHBVC650AV, Expiry Date: March 2020) may also be affected.
Background information
Beginning in July 2015, GlaxoSmithKline Biologicals SA identified an increase in the reporting rate of leakages in CCT syringes at the connection of the syringe tip and the needle hub during vaccine preparation and administration (see Figure 1). The integrity of the leaking syringe and sterility of the contents were not compromised.
A review of GlaxoSmithKline Biologicals SA pharmacovigilance data as of December 14, 2017 did not find evidence that the observed leakage has resulted in vaccination failure (lack of efficacy) or any other patient safety concern. In Canada, the syringe leakage rate is 3 per 100,000 syringes distributed, although the precise frequency of leakage is not known and may be higher.
GlaxoSmithKline Inc. has implemented corrective actions with its syringe suppliers and has introduced improved syringes in its filling operations as of January 2018. However, both the improved and current CCT syringes will be on the market during 2019, with the proportion of potentially affected syringes progressively decreasing towards the end of 2019 by when the current syringes are expected to have been used up.
Data relevant to the administration of lower antigen content are available for HAVRIX and ENGERIX-B
(1 - 2). These data suggest that the administration of half the required antigen dose of HAVRIX or ENGERIX-B will not affect seroprotection or seropositivity. As the probability of a leakage resulting in patients receiving half the required dose is very low, leakage is not expected to impact seroprotection/seropositivity following vaccination.
No dose-range studies are available for TWINRIX, but the immune response to the two antigens in the TWINRIX vaccine was demonstrated to be at least as good as that after vaccination with the monovalent vaccines, HAVRIX and ENGERIX-B
(3), for which data on administration of lower antigen content are available.
For the other vaccines potentially impacted by leakages, it is not possible to assess the likely impact of underdosing on seroprotection/seropositivity. However, for vaccines given in a multi-dose schedule (2-3 priming doses plus booster), it is highly unlikely that each dose will be administered with a leaking syringe.
Regarding the potential risk of overdosing in case of revaccination, the reported adverse events after overdosage with vaccines, including INFANRIX-IPV and INFANRIX-IPV/Hib, BOOSTRIX, BOOSTRIX-POLIO and TWINRIX
(4, 5 ,6, 7), were similar to those reported with the standard dose administration.